Equities Analysts Offer Predictions for TherapeuticsMD, Inc.’s FY2017 Earnings (TXMD)
TherapeuticsMD, Inc. (NASDAQ:TXMD) – Equities researchers at Cantor Fitzgerald boosted their FY2017 earnings estimates for shares of TherapeuticsMD in a research report issued on Tuesday. Cantor Fitzgerald analyst W. Tanner now forecasts that the company will earn ($0.41) per share for the year, up from their prior estimate of ($0.47). Cantor Fitzgerald currently has a “Buy” rating and a $33.00 target price on the stock.
Several other equities analysts also recently commented on the stock. Deutsche Bank AG started coverage on shares of TherapeuticsMD in a research note on Friday, July 21st. They issued a “buy” rating and a $10.00 price objective for the company. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $10.00 price objective on shares of TherapeuticsMD in a research note on Friday, July 21st. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, September 8th. Cowen and Company reissued an “outperform” rating and issued a $13.00 price objective on shares of TherapeuticsMD in a research note on Monday, July 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research note on Monday, August 21st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $15.25.
TherapeuticsMD (NASDAQ TXMD) opened at $5.67 on Friday. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm’s revenue was down 19.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) EPS.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. increased its position in TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after acquiring an additional 67,855 shares during the period. Carl Domino Inc acquired a new position in TherapeuticsMD in the 2nd quarter valued at approximately $235,000. Raymond James Financial Services Advisors Inc. increased its position in shares of TherapeuticsMD by 293.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 112,900 shares of the company’s stock worth $595,000 after buying an additional 84,170 shares during the period. Stifel Financial Corp increased its position in shares of TherapeuticsMD by 377.9% during the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares during the period. Finally, Bamco Inc. NY increased its position in shares of TherapeuticsMD by 126.8% during the second quarter. Bamco Inc. NY now owns 850,000 shares of the company’s stock worth $4,479,000 after buying an additional 475,200 shares during the period. Hedge funds and other institutional investors own 71.40% of the company’s stock.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was purchased at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 23.92% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.